Last reviewed · How we verify
A Phase 1 Study of Intraperitoneal Nanoparticle Paclitaxel in Patients With Peritoneal Malignancies
The purpose of this study is to evaluate the safety, pharmacokinetics and preliminary efficacy of an intraperitoneally administered suspension of nanoparticulate paclitaxel in patients with refractory malignancies principally confined to the peritoneal cavity.
Details
| Lead sponsor | CritiTech, Inc. |
|---|---|
| Phase | Phase 1 |
| Status | COMPLETED |
| Enrolment | 22 |
| Start date | 2008-07 |
| Completion | 2013-05 |
Conditions
- Peritoneal Neoplasms
Interventions
- nanoparticulate paclitaxel
Primary outcomes
- Determine maximum tolerated dose and to assess qualitative and quantitative toxicities — Through last patient visit
Countries
United States